Atlas Private Wealth Management’s United Therapeutics UTHR Stock Holding History

Atlas Private Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-278	Closed	-$47K	–	354
2021 Q1	$47K	Hold	278	–	–	0.03%	190
2020 Q4	$42K	Hold	278	–	–	0.03%	207
2020 Q3	$28K	Hold	278	–	–	0.02%	225
2020 Q2	$34K	Hold	278	–	–	0.03%	220
2020 Q1	$26K	Hold	278	–	–	0.02%	227
2019 Q4	$24K	Buy	+278	New	+$24.5K	0.02%	273

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Atlas Private Wealth Management's UTHR Position: Q2 2021 in Review

Atlas Private Wealth Management sold out of United Therapeutics (UTHR) in Q2 2021, closing a stake of 278 shares — an estimated $47K sold.

Atlas Private Wealth Management first reported a position in UTHR in Q4 2019 and held it in 6 quarters. The position peaked at $47K in Q1 2021. 403 funds tracked by Wall St. Rank hold UTHR as of Q2 2021.

Atlas Private Wealth Management reported no remaining United Therapeutics position as of Q2 2021 after selling out during the quarter.
Atlas Private Wealth Management sold 278 United Therapeutics shares in Q2 2021, an estimated $47K.
Atlas Private Wealth Management first reported a position in United Therapeutics in Q4 2019 and held it in 6 quarters.
Atlas Private Wealth Management's United Therapeutics position peaked at $47K in Q1 2021.
403 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2021.

Based on Atlas Private Wealth Management's 13F filing for Q2 2021, filed 5 Aug 2021.